NeoGenomics, Inc.

Good morning. Welcome to the NeoGenomics fourth quarter and full year 2022 earnings conference call. As a reminder, this call is being webcast live and recorded, and there will be references to a slide presentation in conjunction with remarks. Because there is a short delay between the live telephone audio and the presentation being shown on the webcast, for the best experience, please either use the webcast for both the audio and video content, or if you're dialing by phone, please download the slides on the Investor Relations site at www.ir.neogenomics.com, and advance the slides yourselves. I will now turn the call over to Chris Smith at Neogenomics.

Thanks, Paul, and good morning, everyone. I'd like to welcome you to the Neogenomics Fourth Quarter 2022 Conference Call. Joining me for this call are Jeff Sherman, our Chief Financial Officer, Vassal Sikri, President of our newly created Advanced Diagnostics Division, Warren Stone, President of our Clinical Service Division, and Melody Harris, President of Enterprise Operation. Before we begin our prepared remarks, Jeff will discuss the forward-looking statement and non-GAAP measures used for this call. Jeff?

This conference call includes forward-looking statements about our 2023 initiatives, 2023 financial outlook, growth opportunities, and anticipated operating results and performance. Each forward-looking statement is subject to risk and uncertainties that could cause actual results to differ materially from those projected in sub-statements. Additional information regarding these risk factors appears under the heading Forward-Looking Statements in the press release we issued this morning and in the Risk Factors section in our annual report on Form 10-K for the year ended December 31, 2022, that will be filed with the Securities and Exchange Commission. The forward-looking statements made during this call speak only as of the original date of the call, and we undertake no obligation to update or revise any of these statements. In addition, during this conference call, in order to provide greater transparency regarding our operating performance, we refer to certain non-GAAP financial measures that involve adjustments to GAAP results. The non-GAAP financial measures presented should not be considered to be an alternative to financial measures required by GAAP, should not be considered measures of liquidity and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Any non-GAAP financial measures referenced on this call are reconciled to the most directly comparable GAAP financial measure in a table available in the press release we issued this morning. Please be advised that we are going to limit the number of questions to one per person in order to give more people a chance to ask questions within the one hour that has been allotted for this call.